NL2036639B1 - Preparation method for selenide dihydromyricetin - Google Patents
Preparation method for selenide dihydromyricetin Download PDFInfo
- Publication number
- NL2036639B1 NL2036639B1 NL2036639A NL2036639A NL2036639B1 NL 2036639 B1 NL2036639 B1 NL 2036639B1 NL 2036639 A NL2036639 A NL 2036639A NL 2036639 A NL2036639 A NL 2036639A NL 2036639 B1 NL2036639 B1 NL 2036639B1
- Authority
- NL
- Netherlands
- Prior art keywords
- dmy
- reaction
- selenide
- solution
- sodium selenite
- Prior art date
Links
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 title claims abstract description 186
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 title claims abstract description 93
- 150000003346 selenoethers Chemical class 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000002474 experimental method Methods 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 6
- 239000011734 sodium Substances 0.000 claims abstract description 6
- 238000012512 characterization method Methods 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 42
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 17
- 229960001471 sodium selenite Drugs 0.000 claims description 17
- 235000015921 sodium selenite Nutrition 0.000 claims description 17
- 239000011781 sodium selenite Substances 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 11
- 230000035484 reaction time Effects 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000012298 atmosphere Substances 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 abstract description 6
- 235000017173 flavonoids Nutrition 0.000 abstract description 6
- 239000002904 solvent Substances 0.000 abstract description 5
- 239000003960 organic solvent Substances 0.000 abstract description 4
- 238000003912 environmental pollution Methods 0.000 abstract description 3
- 150000002215 flavonoids Chemical class 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229940082569 selenite Drugs 0.000 abstract 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 239000011669 selenium Substances 0.000 description 12
- 229940091258 selenium supplement Drugs 0.000 description 12
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 11
- 229910052711 selenium Inorganic materials 0.000 description 11
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- -1 flavonoid compound Chemical class 0.000 description 3
- 238000013386 optimize process Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004675 intestinal mucosal permeability Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 235000010955 Hovenia acerba Nutrition 0.000 description 1
- 241001533134 Hovenia acerba Species 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 241000219099 Parthenocissus quinquefolia Species 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- HEILIGJNYTWOHU-UHFFFAOYSA-N ethanol 2-hydroxybenzoic acid Chemical compound CCO.OC(=O)C1=CC=CC=C1O HEILIGJNYTWOHU-UHFFFAOYSA-N 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C391/00—Compounds containing selenium
- C07C391/02—Compounds containing selenium having selenium atoms bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C391/00—Compounds containing selenium
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a preparation method for selenide dihydromyricetin (DMY), falling within the technical field of flavonoids development and utilization. DMY and sodium. selenite are included and used as raw materials to optimize the preparation process through single factor experiments and orthogonal experiments, and the structural characterization, stability, antibacterial and antioxidant activities experiments are performed on selenide DMY by atomic fluorescence, ultraviolet, infrared, TG and, XRD. Water‘ is used, as a solvent, effectively avoiding the problems of high cost and environmental pollution in the use of organic solvents, which is environmentally friendly and low—cost, and has great popularization and application value.
Description
P1958 /NLpd
PREPARATION METHOD FOR SELENIDE DIHYDROMYRICETIN
The present invention relates to the technical field of fla- vonoids development and utilization, in particularly to a prepara- tion method for selenide dihydromyricetin (DMY).
DMY is mostly extracted from a woody liana belonging to Ampe- lopsis, and is also extracted from Hovenia acerba. The main active component of DMY is a flavonoid compound. Studies have confirmed that DMY has many biological activities such as anti-tumor, anti- bacteria, anti-aging, anti-sensitivity, anti-fatigue, scavenging free radicals, anti-oxidation, anti-thrombosis, anti-tumor, anti- inflammatory and lowering blood glucose. DMY can be made into tab- lets, capsules and other products, and added to animal feed to in- crease meat quality and shorten a growth cycle. DMY is a special flavonoid compound, not only having the general characteristics of the flavonoid compound, but having the functions of relieving al- coholism, preventing alcoholic hepatitis and fatty liver, inhibit- ing the deterioration of liver cells and reducing the incidence of liver cancer, which is a good product for protecting liver and re- lieving hangover.
At present, selenium can't be synthesized in human body, which can only be supplemented by exogenous selenium. Organic selenides in selenium supplements can effectively avoid poisoning caused by inorganic selenium, and there are some problems related to poor water solubility (the solubility being only 263.54 mg/L at 25°C), poor stability, poor antioxidant activity, low intestinal mucosal permeability, short half-life in vivo, low pharmacological activity and easy discoloration. These problems have become the main bottleneck factors limiting the wide application of selenium, and the use of organic solvents is high-cost and pollutes the en- vironment.
Technical problem solved
Aiming at the shortcomings of the prior art, the present in- vention provides a preparation method for selenide DMY, which solves the problems of poor water sclubility, poor stability, poor antioxidant activity, low intestinal mucosal permeability, short half-life in vivo, low pharmacological activity, easy discolora- tion and high cost and environmental pollution caused by the use of organic solvents.
In order to achieve the above objectives, the present inven- tion is realized by the following technical solutions. A prepara- tion method for selenide DMY includes DMY and sodium selenite. DMY and sodium selenite are used as raw materials to optimize the preparation process through single factor experiments and orthogo- nal experiments, and the structural characterization, stability, antibacterial and antioxidant activities experiments are performed on selenide DMY by atomic fluorescence, ultraviolet, infrared, TG and XRD.
Preferably, the material ratio in the S3 may also be 1:0.25, 1:0.5, 1:1 or 1:2, the reaction time may also be 40, 60, 80 or 100 min, and the reaction temperature may also be 15, 35, 55 or 75°C; and in the reaction step of the S4, HCl is utilized to adjust the pH to 8, 7 or 2.
Preferably, a reaction condition of the S3 is that the reac- tion is carried out in an inert atmosphere (such as a nitrogen at- mosphere) to prevent oxygen from interfering with the reaction.
Preferably, a preparation method for selenide DMY includes the following steps:
Sl: material preparation preparing enough DMY and sodium selenite in proportion;
S2: solution selection selecting a saturated Na,CO; solution to cause reactants to be fully dissolved and reacted;
S3: reaction conditions setting a material ratio of DMY to sodium selenite as 1:3,
with a reaction time of 120 min and a reaction temperature of 95°C; and
S4: reaction steps a: dissolving a portion of DMY in the saturated Na;CO; solu- tion to obtain a DMY solution, b: gradually adding three portions of sodium selenite into the DMY solution and stirring a reaction mixture, c: reacting the mixture for 120 min at a reaction temperature of 95°C, and heating and refluxing the same, and d: adjusting a pH with HCl after the reacting, centrifuging the mixture, sequentially eluting the same with boiling distilled water and iced distilled water, and performing vacuum drying on the same to obtain powdery solid.
The present invention provides a preparation method for sele- nide DMY. The present invention has the following advantageous ef- fects. 1. According to the present invention, the preparation of selenide DMY by using water as the solvent has the advantages of environmental protection and low cost, and the stability and bio- logical activity of selenide DMY obtained by structural modifica- tion of DMY with selenium are improved. The preparation technology and related parameters of selenide DMY have a simple technological process, safe operations and low cost in production, which is suitable for batch processing, and can be widely used in experi- ments or industrial production. Water, selected as the solvent, effectively avoiding the problems of high cost and environmental pollution caused by the use of organic solvents, is environmental- ly friendly and low-cost, and has great popularization and appli- cation value. 2. According to the present invention, the active substance
DMY extracted and purified from natural product Vine tea is used as a substrate, and Na,CO; is used as a selenizing agent, and the structure of DMY is modified by selenization to prepare the organ- ic selenide DMY. The thermal stability of the obtained selenide
DMY in a range of 250°C-370°C is better than that of DMY, and the stability in an aqueous solution is good, and the antioxidant ac-
tivity is better than that of DMY, which is positively related to a sample amount. Therefore, the organic selenide DMY has good thermal stability, aqueous solution stability, antibacterial ac- tivity and strong antioxidant activity.
FIG. 1 is an ultraviolet spectrogram of the influence of a heating temperature on the stability of selenide DMY according to the present invention;
FIG. 2 is an ultraviolet spectrogram of the influence of a pH on the stability of selenide DMY according to the present inven- tion;
FIG. 3 is an ultraviolet spectrogram of the influence of a heating time on the stability of selenide DMY according to the present invention; and
FIG. 4 is a graph showing scavenging rates of DMY and sele- nide DMY to «OH radicals according to the present invention.
Technical solutions in the examples of the present invention will be described clearly and completely in the following with reference to the attached drawings in the examples of the present invention. Obviously, all the described examples are only some, rather than all examples of the present invention. Based on the examples in the present invention, all other examples obtained by those of ordinary skill in the art without creative efforts belong to the scope of protection of the present invention.
Example 1
As shown in FIGS. 1-4, an example of the present invention provides a preparation method for selenide DMY, including DMY and sodium selenite. DMY and sodium selenite are used as raw materials to optimize the preparation process through single factor experi- ments and orthogonal experiments, and the structural characteriza- tion, stability, antibacterial and antioxidant activities experi- ments are performed on selenide DMY by atomic fluorescence, ultra- violet, infrared, TG and XRD.
The material ratio in the 33 may also be 1:0.25, 1:0.5, 1:1 or 1:2, the reaction time may also be 40, 60, 80 or 100 min, and the reaction temperature may also be 15, 35, 55 or 75°C.
In the reaction step of the S4, HCl is utilized to adjust the
PH to 8, 7 or 2.
A reaction condition of the S3 is that the reaction is car- ried out in an inert atmosphere (such as a nitrogen atmosphere) to 5 prevent oxygen from interfering with the reaction.
Example 2
As shown in FIGS. 1-4, an example of the present invention provides a preparation method for selenide DMY, including the fol- lowing steps.
At S1: material preparation enough DMY and sodium selenite were prepared in proportion.
At S2: solution selection a saturated Na:CO: solution was selected to cause reactants to be fully dissolved and reacted.
At S3: reaction conditions a material ratio of DMY was set to sodium selenite as 1:3, with a reaction time of 120 min and a reaction temperature of 95°C.
At S4: reaction steps a: a portion of DMY was dissolved in the saturated Na,CO; so- lution to obtain a DMY solution, b: three portions of sodium selenite were gradually added in- to the DMY solution and a reaction mixture was stirred, c: the mixture was reacted for 120 min at a reaction tempera- ture of 95°C, heated and refluxed, and d: a pH was adjusted with HCl after the reacting, centri- fuged, sequentially eluted with boiling distilled water and iced distilled water, and vacuum dried to obtain powdery solid.
Example 3
As shown in FIGS. 1-4, an example of the present invention provides a preparation method, experiments and optimization for selenide DMY, including the following steps. (1) Single factor experiments: DMY and sodium selenite were weighed in proportion, an appropriate amount of distilled water was taken as a solvent, a pH of a reaction system was adjusted with a saturated Na:CO: solution, the reaction system was heated and refluxed, the pH was adjusted with HCl after the reaction, and the mixture was centrifuged, sequentially eluted with boiling dis-
tilled water and iced distilled water, and vacuum dried to obtain yellow-brown powdery solid. The single factor experiments were performed with material ratios of 1:0.25, 1:0.5, 1:1, 1:2 and 1:3 for reaction times of 40, 60, 80, 100 and 120 min at reaction tem- peratures of 15, 35, 55, 75 and 95°C, and pHs of the reaction sys- tem were 8, 7 and 2. When the material ratios were 1:0.25, 1:0.5, 1:1, 1:2 and 1:3, selenium source utilization ratios of selenide
DMY were 0.08%, 0.21%, 0.23%, 1.12% and 1.50%; when the reaction times were 40, 60, 80, 100 and 120 min, selenium source utiliza- tion rates of selenide DMY were 2.73%, 0.89%, 0.54%, 0.17% and 1.58%; and when the reaction temperatures were 15, 35, 55, 75 and 95°C, selenium source utilization rates of selenide DMY were 0.003%, 0.006%, 0.51%, 27.44% and 29.38%; when the pHs of the re- action system were 8, 7 and 2, selenium source utilization rates of selenide DMY were 0.54%, 1.43% and 0.07%; and finally, the se- lenium source utilization rate of selenide DMY was 29.38% when the ratio was 1:3, the reaction time was 120 min and the reaction tem- perature was 95°C. {2) Orthogonal experiments: according to the results of the single factor experiments, the material ratios were 1:0.25, 1:0.5, 1:1 and 1:2, the reaction times were 60, 80, 100 and 120 min, the reaction temperatures were 35, 55, 75 and 95°C, and four-factor and four-level orthogonal experiments were designed for the reaction system at pHs of 2, 7, 8 and 9. The utilization rates of selenium source were taken as performance indexes, the optimized process parameters for preparing selenide DMY were determined by SPSS23.0 analysis. The test results were shown in Table 1. (3) An optimized process for preparing selenide DMY: DMY and sodium selenite were weighted according to a material ratio of 1:0.25, an appropriate amount of distilled water was taken as a solvent, a pH of a reaction system was adjusted to 8, the reaction system was heated and refluxed at 95°C for 120 min, the pH was ad- justed with HCl after the reaction, and the mixture was centri- fuged, sequentially eluted with boiling distilled water and iced distilled water, and vacuum dried to obtain yellow-brown powdery solid. Under the optimized process conditions, a selenium source utilization rate of the prepared selenide DMY was 80.73%. A ultra- violet spectrum showed that there were structural characteristic peaks of flavonoids (208.5 nm) and flavonols (358.5 nm) in sele- nide DMY. An infrared spectrum showed that a benzene ring struc- ture still existed in selenide DMY, and C=0, -OH and Se* of DMY were selenized to form new rings, and a new characteristic absorp- tion peak of Se-0O appeared. TG showed that the thermal stability of selenide DMY was higher than that of DMY in a range of 250°C- 370°C, and XRD showed that crystal diffraction peaks of selenide
DMY were 8.96°, 11.92°, 14.58°, 23.46°, 26.88°, 29.62°, 36.14°, 43.54° and 45.26°. Selenide DMY is formed by chemical reactions, not simple physical mixing. (4) Stability experiments: 15 mL of sample solution was taken in a small test tube, heating temperatures, pHs and heating times were changed sequentially, and an ultraviolet spectrum was meas- ured in a range of 250-500 nm, where the heating temperatures were 10, 35, 55, 75, 95 and 100°C, pH values were 2, 4, 6, 7, 8, 10 and 12, and the heating timed were 10, 20, 30, 40, 50 and 60 min. The results of stability experiments were shown in FIGS. 1-3. From
FIG. 1, it could be seen that when the temperature was 10°C-100°C, positions of characteristic absorption peaks of selenide DMY did not change obviously, indicating that selenide DMY existed stably without obvious decomposition. From FIG. 2, it could be seen that characteristic absorption peaks of a selenide DMY aqueous solution with a PH value of 6 were consistent with that with a pH adjusted to be acidic, but different from that with pHs adjusted to be neu- tral, weakly alkaline and alkaline, indicating that selenide DMY was stable under acidic conditions and unstable under neutral and slightly alkaline conditions. From FIG. 3, it could be seen that positions of the characteristic absorption peaks of selenide DMY were basically consistent when the heating time was 10 min-60 min, indicating that it existed stably without decomposition. The sta- bility experiments showed that the selenide DMY aqueous solution had good stability. (5) Antioxidant activity experiments: 2 mL of sample solu- tions with different concentration gradients, 2 mL of 6 mmol/L
FesS0, solution, 2 mL of 6 mmol/L salicylic acid-ethanol solution and 2 ml of 6 mmol/L LH:0: solution were added to an appropriate amount of small test tubes, then an absorbance value was measured at 510 nm after holding in water bath at 37°C for 30 min, and an «OH radical scavenging rate (%) was calculated. The experimental results were shown in FIG. 4. In experimental ranges, when the sample concentration was 300 pg/mL, the scavenging rates of ¢CH radicals of DMY and selenide DMY were the highest, which were 31.40% and 56.40% respectively. The scavenging rate of selenide
DMY on sOH radicals was better than that of DMY, and the antioxi- dant experiments showed that selenide DMY had good antioxidant ac- tivity.
Table 1 Orthogonal experiment results
Serial A material B reaction Dreac temperature number ratio time (min) (°C) tion pH 1 2 3 1 1{1:0.25) 1{60) 1{35) 1{2} 12.63% 12.33% 12.55% 2 1 2{80) 2(55) 2(7) 0.54% 0.49% 0.51% 3 1 3{100} 3{75) 3{8) 50.59% 52.38% 50.89% 4 1 4{120) 4(95) 4(9) 71.88% 73.64% 72.76% 5 2{1:0.5) 1 2 3 0.19% 0.17% 0.15% 6 2 2 1 4 1.42% 2.08% 2.29% 7 2 3 4 1 3.23% 3.20% 3.22% 8 2 4 3 2 54.12% 54.42% 52.20% 9 3(1:1) 1 3 4 20.32% 20.44% 20.48% 10 3 2 4 3 21.02% 20.73% 20.87% 11 3 3 1 2 0.07% 0.07% 0.08% 12 3 4 2 1 1.13% 1.10% 0.72% 13 4(1:2) 1 4 2 7.31% 7.45% 7.39% 14 4 2 3 1 0.31% 0.29% 0.24% 4 3 2 4 1.75% 1.72% 1.73% 16 4 4 1 3 0.28% 0.29% 0.30% "While examples of the present invention have been shown and _ 15 described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations may be made herein without departing from the principles and spirit of the present invention, the scope of which is defined by the ap- pended claims and equivalents thereof.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2036639A NL2036639B1 (en) | 2023-12-22 | 2023-12-22 | Preparation method for selenide dihydromyricetin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2036639A NL2036639B1 (en) | 2023-12-22 | 2023-12-22 | Preparation method for selenide dihydromyricetin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL2036639A NL2036639A (en) | 2024-01-26 |
| NL2036639B1 true NL2036639B1 (en) | 2024-08-13 |
Family
ID=89621215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2036639A NL2036639B1 (en) | 2023-12-22 | 2023-12-22 | Preparation method for selenide dihydromyricetin |
Country Status (1)
| Country | Link |
|---|---|
| NL (1) | NL2036639B1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2005955A4 (en) * | 2006-03-31 | 2009-10-28 | Fulin Fan | FORMULATIONS OF AN UNSATURATED SALT OF AMPELOPSIN AND ITS APPLICATION |
| CN108409621A (en) * | 2017-02-10 | 2018-08-17 | 上海爱启生态科技有限公司 | A kind of dihydromyricetin selenium compound for treating liver cancer and related liver disease |
| CN111454240B (en) * | 2020-04-30 | 2023-05-16 | 上海爱启医药技术有限公司 | Process for preparing diselenide compounds |
| CN111393408A (en) * | 2020-04-30 | 2020-07-10 | 上海爱启医药技术有限公司 | Method for preparing natural flavone selenium |
| CN112570726B (en) * | 2020-11-24 | 2023-07-28 | 山东省分析测试中心 | Dihydromyricetin functionalized silver nanoparticles and its green synthesis method and application |
| CN112451514A (en) * | 2020-11-26 | 2021-03-09 | 江西农业大学 | Dihydromyricetin nano-selenium and preparation method and application thereof |
-
2023
- 2023-12-22 NL NL2036639A patent/NL2036639B1/en active
Also Published As
| Publication number | Publication date |
|---|---|
| NL2036639A (en) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL2036639B1 (en) | Preparation method for selenide dihydromyricetin | |
| CZ279815B6 (en) | Process for preparing d,1-5-methyltetrahydrofolic acid or salts thereof being acceptable from pharmaceutical point of view | |
| Bolognesi et al. | The crystal and molecular structure of two models of catalytic flavo (co) enzyme intermediates | |
| WO2021217825A1 (en) | Method for preparing diselenide compound | |
| Forrest et al. | Isolation and characterization of a yellow pteridine from the blue-green alga, Anacystis nidulans | |
| CN105713104B (en) | A kind of synthesis and its application of selenizing Fenugreek Polysaccharides | |
| Szczerba et al. | Mechanochemical synthesis of bismuth active pharmaceutical ingredients, bismuth (III) gallate and bismuth citrate | |
| CN111848593B (en) | Water-soluble isoorientin-zinc complex and preparation method and application thereof | |
| CN109096053B (en) | Synthesis method of OLED intermediate and semiconductor material 1-hydroxypyrene | |
| Erzunov et al. | Investigation of catalytic processes of thio-compounds conversion to disulfides using novel butyl/butoxy-phthalocyaninates of d-metals | |
| CN118994129B (en) | Vitamin C derivative and preparation method and application thereof | |
| CN109912608A (en) | Hydroxyl replaces click to cough up complex and preparation method thereof | |
| Lambein et al. | Isolation and characterization of 2-(β, D-glucopyranosyl)-4alanyl-3-Isoxazolin-5-one: A second UV-sensitive heterocyclic α-amino acid from Pisum sativum L. | |
| CN108473509A (en) | The preparation method of C-Met tyrosine kinase inhibitors | |
| Nijenhuis et al. | PHOTOCHEMICAL AROMATIC HYDROXYLATION OF FLAVINS UNDER ANAEROBIC CONDIIONS | |
| CN109929106B (en) | A kind of fluorescent probe for detecting thiocyanate and its preparation method and application | |
| Silber et al. | Photoreactions of riboflavin in the presence of 2, 4-dichlorophenoxyacetic acid (2, 4-D) | |
| CN113896665A (en) | Preparation method of 2-chloro-1-methyl-4- (methylsulfonyl) benzene | |
| Alejo-Armijo et al. | Generalization of the anthocyanins kinetics and thermodynamics multistate to 2, 6-bis (2-hydroxybenzylidene) cyclohexanones | |
| YAMAJI et al. | The Synthesis of 2-Substituted 1, N6-Etheno-adenosine-3', 5'-cyclic Phosphate by Ring Reclosure of Alkali-hydrolizate of 1, N6-Etheno-adenosine-3', 5'-cyclic Phosphate | |
| Henry | Crystalline Complexes of 1, 3, 5-Trinitrobenzene and Alkali Sulfites | |
| Elizbarashvili et al. | Synthesis of macrocyclic polyazomethines | |
| CN119841879B (en) | Supermolecule arbutin nicotinamide, preparation method thereof and daily chemical product | |
| Vlasenko et al. | α-Amino acid-assisted autoxidation of naphthalene proton sponge affording 1, 4-naphthoquinone nitrogen derivatives | |
| Gavalás-Olea et al. | Enzymatic synthesis and characterization of chlorophyllide derivatives as possible internal standards for pigment chromatographic analysis |